Form 4: Spyre Therapeutics CFO Trades Shares

Spyre Therapeutics, Inc. CFO Scott L. Burrows reports transactions involving common stock and stock options.

Summary

• Scott L. Burrows, Chief Financial Officer of Spyre Therapeutics, Inc. (SYRE), reported transactions on June 25, 2026.
• Burrows acquired 15,000 shares of common stock at a price of $14.50 per share.
• He also disposed of 5,000 shares at a weighted average price of $87.12 and 10,000 shares at $87.14.
• Following these transactions, Burrows beneficially owns 97,994 shares of common stock directly.
• Additionally, he holds a stock option to purchase 15,000 shares of common stock at an exercise price of $14.50, with an expiration date of September 1, 2033.
• His total beneficial ownership of common stock, including restricted stock units (RSUs), is 112,994 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While the CFO acquired shares at a lower price, indicating potential confidence, they also sold a significant number of shares at a higher price, suggesting profit-taking.

Positives

• Acquisition of 15,000 shares at a significantly lower price ($14.50) than the current trading price, indicating a potential long-term investment by management.
• The CFO's continued beneficial ownership of a substantial number of shares (112,994) suggests confidence in the company's future prospects.

Negatives

• Disposal of 15,000 shares at prices significantly higher than the acquisition price, which could be interpreted as profit-taking by management.

Risks

• The filing does not explicitly mention any risks or challenges.
• The disposal of shares by a key executive could be perceived negatively by the market, although the acquisition at a lower price mitigates this concern.

Future Outlook

The filing does not contain forward-looking statements or guidance. However, the acquisition of shares by the CFO at a lower price and the vesting schedule of RSUs suggest a long-term commitment and potential future value realization.

Industry Context

StockSavvy.ai notes that insider transactions, such as those reported on Form 4, are closely watched by investors as they can provide insights into management's confidence in the company's performance and future prospects. The acquisition of shares at a lower price by the CFO of Spyre Therapeutics, Inc. could be interpreted as a positive signal.

Stakeholder Impact

• Shareholders: May interpret the CFO's share acquisition as a positive signal of confidence, while the share disposal could be seen as profit-taking.
• Employees: The CFO's continued employment and equity holdings are generally positive for employee morale and alignment.
• Creditors: No direct impact from this filing.
• Suppliers: No direct impact from this filing.
• Customers: No direct impact from this filing.

Next Steps

• Vesting of remaining RSUs on September 1, 2026, and September 1, 2027.
• Continued vesting of stock options over the next three years.
• Potential future transactions by the reporting person.

Key Dates

Keywords

Spyre Therapeutics, SYRE, Form 4, Insider Trading, Stock Options, Common Stock, Beneficial Ownership, CFO, Scott L. Burrows, SEC Filing